New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
Rev. Soc. Bras. Med. Trop
; 48(3): 235-242, May-Jun/2015. tab, graf
Article
en En
| LILACS
| ID: lil-749870
Biblioteca responsable:
BR1.1
ABSTRACT
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Contexto en salud:
2_ODS3
Problema de salud:
2_cobertura_universal
/
2_enfermedades_transmissibles
Asunto principal:
Anfotericina B
/
Sistemas de Liberación de Medicamentos
/
Leishmaniasis Visceral
/
Antiprotozoarios
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Asunto de la revista:
MEDICINA TROPICAL
Año:
2015
Tipo del documento:
Article
País de afiliación:
Brasil